Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) had its price target lowered by stock analysts at Morgan Stanley to $30.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price target indicates a potential upside of 479.15% from the stock’s previous close.
Other analysts have also recently issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. HC Wainwright began coverage on Eikon Therapeutics in a research report on Friday, October 16th. They set a “buy” rating and a $23.00 target price on the stock. Wedbush cut their price target on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a report on Friday, August 14th. Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 16th. Finally, Wall Street Zen upgraded Eikon Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Eikon Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $24.33.
Check Out Our Latest Stock Analysis on Eikon Therapeutics
Eikon Therapeutics Stock Performance
NASDAQ EIKN traded up $0.03 during trading on Wednesday, hitting $5.18. 156,220 shares of the company’s stock traded hands, compared to its average volume of 438,029. The stock has a market capitalization of $280.70 million and a price-to-earnings ratio of -1.25. Eikon Therapeutics has a 12-month low of $4.95 and a 12-month high of $17.40. The business has a 50 day moving average of $7.31 and a 200-day moving average of $9.99.
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. On average, analysts expect that Eikon Therapeutics will post -7.04 EPS for the current year.
Insider Transactions at Eikon Therapeutics
In other news, major shareholder Group Iv Gp Lp Column purchased 89,200 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the acquisition, the insider directly owned 89,200 shares in the company, valued at approximately $1,031,152. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in Eikon Therapeutics during the second quarter valued at $28,000. Entropy Technologies LP purchased a new position in Eikon Therapeutics during the third quarter worth about $125,000. Integrated Wealth Concepts LLC bought a new position in Eikon Therapeutics in the 2nd quarter worth about $142,000. Citadel Advisors LLC bought a new position in Eikon Therapeutics in the 2nd quarter worth about $170,000. Finally, Deutsche Bank AG bought a new position in Eikon Therapeutics in the 2nd quarter worth about $281,000.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
See Also
- Five stocks we like better than Eikon Therapeutics
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
